Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: A population-based study
Main finding · PRD in statin responseResult — go to the resultPRD 5.18 percentage points 95% CI 4.79–5.57Authors' conclusion
Most of the studied comorbidities and co-medications did not have a clinically important effect on statin response, suggesting no need to modify treatment regimens. However, use of metformin was associated with a significantly enhanced LDL-C response to statins
Study context
- Population
- Simvastatin or atorvastatin initiators with pre-statin and on-statin low-density lipoprotein cholesterol (LDL-C), Denmark, 2008–2018
- Participants
- 89,006 participants
- Exposure
- LDL-C response to statins according to 175 chronic comorbidities and 99 co-medications
- Outcome
- Statin response: percentage reduction in LDL-C; PRD by comorbidity and co-medication (clinically important: PRD ≥5 percentage points)
Methodological detailspopulation-based
- Population-based
Main finding
PRD in statin response
Percentage reduction differences (PRD)
5.18 percentage points
95% CI 4.79–5.57
As reported in the abstract
Observational data: associations, not effects.
Original publication
Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: A population-based study. Am Heart J. Published 6 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →